This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yang, J. Articles by Hait, W. N. Search for Related Content PubMed PubMed Citation Articles by Yang, J. Articles by Hait, W. N.

Disruption of the EF-2 Kinase/Hsp90 Protein Complex

A Possible Mechanism to Inhibit Glioblastoma by Geldanamycin¹

University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, Departments of Medicine and Pharmacology, The Cancer Institute of New Jersey [J. Y., J-M. Y., M. I., W. N. H.] and School of Public Health [W. J. S., Y. L.], New Brunswick, New Jersey, 08901

Glioblastoma multiforme is the most treatment-resistant brain tumor. Elongation factor-2 (EF-2) kinase (calmodulin kinase III) is a unique protein kinase that is overexpressed in glioma cell lines and in human surgical specimens. Several mitogens activate this kinase and inhibitors block mitogen activation and produce cell death. Geldanamycin (GA) is a benzoquinone ansamycin antibiotic that disrupts Hsp90-protein interactions. Because EF-2 kinase is chaperoned by Hsp90, we investigated the effects of GA on the viability of glioma cells, the expression of EF-2 kinase protein, and the interaction between Hsp90 and EF-2 kinase. GA was a potent inhibitor of the clonogenicity of four glioma cells lines with IC₅₀s ranging from 1 to 3 nM. 17-allylamino-17-demethoxygeldanamycin (17-AAG), a less toxic and less potent derivative of GA, inhibited the clonogenicity of glioma cells with IC₅₀ values of 13 nM in C6 cells and 35 nM in T98G cells. Treatment of cell lines for 24–48 h of GA or 17-AAG disrupted EF-2-kinase/Hsp90 interactions as measured by coimmunoprecipitation, resulting in a decreased amount of recoverable kinase in cell lysates. The ability of GA to inhibit the growth of glioma cells was abrogated by overexpressing EF-2 kinase. In addition, 17-AAG significantly inhibited the growth of a glioma xenograft in nude mice. These studies demonstrate for the first time the activity of GAs against human gliomas in vitro and in vivo and suggest that destruction of EF-2 kinase may be an important cytotoxic mechanism of this unique class of drug.

This article has been cited by other articles:

				C. M.-E. Sauvageot, J. L. Weatherbee, S. Kesari, S. E. Winters, J. Barnes, J. Dellagatta, N. R. Ramakrishna, C. D. Stiles, A. L.-J. Kung, M. W. Kieran, et al. Efficacy of the HSP90 inhibitor 17-AAG in human glioma cell lines and tumorigenic glioma stem cells Neuro-oncol, January 1, 2009; 11(2): 109 - 121. [Abstract] [Full Text] [PDF]

				K. M. Castorena, S. A. Weeks, K. A. Stapleford, A. M. Cadwallader, and D. J. Miller A Functional Heat Shock Protein 90 Chaperone Is Essential for Efficient Flock House Virus RNA Polymerase Synthesis in Drosophila Cells J. Virol., August 15, 2007; 81(16): 8412 - 8420. [Abstract] [Full Text] [PDF]

				B. J. Weigel, S. M. Blaney, J. M. Reid, S. L. Safgren, R. Bagatell, J. Kersey, J. P. Neglia, S. P. Ivy, A. M. Ingle, L. Whitesell, et al. A Phase I Study of 17-Allylaminogeldanamycin in Relapsed/Refractory Pediatric Patients with Solid Tumors: A Children's Oncology Group Study Clin. Cancer Res., March 15, 2007; 13(6): 1789 - 1793. [Abstract] [Full Text] [PDF]

				G. S. Nowakowski, A. K. McCollum, M. M. Ames, S. J. Mandrekar, J. M. Reid, A. A. Adjei, D. O. Toft, S. L. Safgren, and C. Erlichman A phase I trial of twice-weekly 17-allylamino-demethoxy-geldanamycin in patients with advanced cancer. Clin. Cancer Res., October 15, 2006; 12(20): 6087 - 6093. [Abstract] [Full Text] [PDF]

				H. Wu, J.-M. Yang, S. Jin, H. Zhang, and W. N. Hait Elongation factor-2 kinase regulates autophagy in human glioblastoma cells. Cancer Res., March 15, 2006; 66(6): 3015 - 3023. [Abstract] [Full Text] [PDF]

				M. W. Graner and D. D. Bigner Chaperone proteins and brain tumors: Potential targets and possible therapeutics Neuro-oncol, July 1, 2005; 7(3): 260 - 278. [Abstract] [PDF]

				S. Arora, J.-M. Yang, and W. N. Hait Identification of the Ubiquitin-Proteasome Pathway in the Regulation of the Stability of Eukaryotic Elongation Factor-2 Kinase Cancer Res., May 1, 2005; 65(9): 3806 - 3810. [Abstract] [Full Text] [PDF]

				Y. Nobukuni, K. Kohno, and K. Miyagawa Gene Trap Mutagenesis-based Forward Genetic Approach Reveals That the Tumor Suppressor OVCA1 Is a Component of the Biosynthetic Pathway of Diphthamide on Elongation Factor 2 J. Biol. Chem., March 18, 2005; 280(11): 10572 - 10577. [Abstract] [Full Text] [PDF]

				M. P. Goetz, D. Toft, J. Reid, M. Ames, B. Stensgard, S. Safgren, A. A. Adjei, J. Sloan, P. Atherton, V. Vasile, et al. Phase I Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients With Advanced Cancer J. Clin. Oncol., February 20, 2005; 23(6): 1078 - 1087. [Abstract] [Full Text] [PDF]

				S. Arora, J.-M. Yang, R. Utsumi, T. Okamoto, T. Kitayama, and W. N. Hait P-Glycoprotein Mediates Resistance to Histidine Kinase Inhibitors Mol. Pharmacol., September 1, 2004; 66(3): 460 - 467. [Abstract] [Full Text] [PDF]

				S. Arora, J.-M. Yang, T. G. Kinzy, R. Utsumi, T. Okamoto, T. Kitayama, P. A. Ortiz, and W. N. Hait Identification and Characterization of an Inhibitor of Eukaryotic Elongation Factor 2 Kinase against Human Cancer Cell Lines Cancer Res., October 15, 2003; 63(20): 6894 - 6899. [Abstract] [Full Text] [PDF]

				J. S. Russell, W. Burgan, K. A. Oswald, K. Camphausen, and P. J. Tofilon Enhanced Cell Killing Induced by the Combination of Radiation and the Heat Shock Protein 90 Inhibitor 17-Allylamino-17- Demethoxygeldanamycin: A Multitarget Approach to Radiosensitization Clin. Cancer Res., September 1, 2003; 9(10): 3749 - 3755. [Abstract] [Full Text] [PDF]

				I. A. Vasilevskaya, T. V. Rakitina, and P. J. O'Dwyer Geldanamycin and its 17-Allylamino-17-Demethoxy Analogue Antagonize the Action of Cisplatin in Human Colon Adenocarcinoma Cells: Differential Caspase Activation as a Basis for Interaction Cancer Res., June 15, 2003; 63(12): 3241 - 3246. [Abstract] [Full Text] [PDF]

				W. B. Pratt and D. O. Toft Regulation of Signaling Protein Function and Trafficking by the hsp90/hsp70-Based Chaperone Machinery Experimental Biology and Medicine, February 1, 2003; 228(2): 111 - 133. [Abstract] [Full Text] [PDF]

				B Jones, E Aird, H Colyer, J Dobbs, R Harris, P Hoskin, A Mckenzie, and C West United Kingdom Radiation Oncology 1 Conference (UKRO 1): Accuracy and uncertainty in radiotherapy Br. J. Radiol., April 1, 2002; 75(892): 297 - 306. [Full Text] [PDF]

				H.-L. Xu, D. L. Feinstein, R. A. Santizo, H. M. Koenig, and D. A. Pelligrino Agonist-specific differences in mechanisms mediating eNOS-dependent pial arteriolar dilation in rats Am J Physiol Heart Circ Physiol, January 1, 2002; 282(1): H237 - H243. [Abstract] [Full Text] [PDF]